U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H21ClFN3O3S
Molecular Weight 461.937
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-5108

SMILES

OC(=O)[C@@]3(CC1=NC(NC2=NC=CS2)=CC=C1)CC[C@@H](CC3)OC4=CC=CC(Cl)=C4F

InChI

InChIKey=LCVIRAZGMYMNNT-VVONHTQRSA-N
InChI=1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15,20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6,11-12,15H,7-10,13H2,(H,28,29)(H,25,26,27)/t15-,22-

HIDE SMILES / InChI

Molecular Formula C22H21ClFN3O3S
Molecular Weight 461.937
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20053775

MK-5108 is a small molecule inhibitor of AuroraA kinase with high selectivity versus Aurora-B and C. It was tested in phase I study against advanced or refractory solid tumors both as a monotherapy or in combination with docetaxel, but this study was terminated early due to toxicities at MK-5108 doses below the anticipated PK exposure target.

Originator

Curator's Comment: Drug VX-689 was developed by Vertex Pharmaceuticals and licensed to Merck in 2009

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.064 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11 μM
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
20 μM
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
25 μM
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
28.9 μM
1500 mg 2 times / day multiple, oral
dose: 1500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.8 μM
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
50.2 μM
1800 mg 2 times / day multiple, oral
dose: 1800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
75.7 μM × h
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
95.5 μM × h
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
115.9 μM × h
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
130.7 μM × h
1500 mg 2 times / day multiple, oral
dose: 1500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
31.2 μM × h
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
234.4 μM × h
1800 mg 2 times / day multiple, oral
dose: 1800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.7 h
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.1 h
800 mg 2 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FASTED
8.3 h
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.4 h
1500 mg 2 times / day multiple, oral
dose: 1500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.3 h
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.6 h
1800 mg 2 times / day multiple, oral
dose: 1800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MK-5108 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
2010 Jan
Patents

Patents

Sample Use Guides

In a randomized phase I study of against advanced or refractory solid tumors MK-5108 was administered p.o. BID Q12h on days 1-2 in 14-21 day cycles either alone (200 to 1800 mg) or in combination (100 to 225 mg) with IV docetaxel 60 mg/m(2).
Route of Administration: Oral
Recombinant His-tagged human Aurora-A protein was expressed in Escherichia coli and was purified with HisTrap HP column (GE Healthcare). The Aurora-A assay reaction was conducted in the presence of 20 μmol/L ATP, 25 μmol/L Tetra-Kemptide [RRR(GLRRASLG)4R-NH2], 1.0 μCi per well [gamma-33P]-ATP, 0.1 ng per well Aurora-A in 50 mmol/L Tris-HCl (pH 7.4), 15 mmol/L Mg(OAc)2, and 0.2 mmol/L EDTA at 30°C for 40 min. To investigate the inhibition mode of MK-5108 for Aurora-A, the IC50 values of MK-5108 were determined in the presence of different concentrations of ATP. Then, the IC50 value was plotted as a function of ATP concentration to analyze the effect of ATP concentration on the IC50 value of MK-5108.
Substance Class Chemical
Created
by admin
on Wed Apr 02 16:29:47 GMT 2025
Edited
by admin
on Wed Apr 02 16:29:47 GMT 2025
Record UNII
H8J407531S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK 5108
Preferred Name English
MK-5108
Common Name English
VX-689
Code English
CYCLOHEXANECARBOXYLIC ACID, 4-(3-CHLORO-2-FLUOROPHENOXY)-1-((6-(2-THIAZOLYLAMINO)-2-PYRIDINYL)METHYL)-, TRANS-
Common Name English
MK5108
Code English
Code System Code Type Description
EPA CompTox
DTXSID901026054
Created by admin on Wed Apr 02 16:29:47 GMT 2025 , Edited by admin on Wed Apr 02 16:29:47 GMT 2025
PRIMARY
CAS
1010085-13-8
Created by admin on Wed Apr 02 16:29:47 GMT 2025 , Edited by admin on Wed Apr 02 16:29:47 GMT 2025
PRIMARY
PUBCHEM
24748204
Created by admin on Wed Apr 02 16:29:47 GMT 2025 , Edited by admin on Wed Apr 02 16:29:47 GMT 2025
PRIMARY
DRUG BANK
DB12556
Created by admin on Wed Apr 02 16:29:47 GMT 2025 , Edited by admin on Wed Apr 02 16:29:47 GMT 2025
PRIMARY
FDA UNII
H8J407531S
Created by admin on Wed Apr 02 16:29:47 GMT 2025 , Edited by admin on Wed Apr 02 16:29:47 GMT 2025
PRIMARY
ChEMBL
CHEMBL3182444
Created by admin on Wed Apr 02 16:29:47 GMT 2025 , Edited by admin on Wed Apr 02 16:29:47 GMT 2025
PRIMARY
NCI_THESAURUS
C90585
Created by admin on Wed Apr 02 16:29:47 GMT 2025 , Edited by admin on Wed Apr 02 16:29:47 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
A selective and potent inhibitor of Aurora A kinase.